British pharmaceutical company GSK has announced that the European Medicines Agency (EMA) will be reviewing its new treatment for a common type of womb cancer. The drug, dostarlimab, which is marketed as Jemperli, will be reviewed for potential approval in the European market. The monoclonal antibody is used in combination with traditional chemotherapy to treat women with advanced or recurring forms of endometrial cancer, which forms in the inner lining of the uterus.
Endometrial cancer is the sixth most common cancer in women, with 417,000 cases reported worldwide in 2020, according to the World Cancer Research Fund International. This cancer affects the endometrium, the lining of the uterus, and can often be diagnosed early if women seek medical advice when they experience symptoms such as abnormal vaginal bleeding or pelvic pain. However, some cases of endometrial cancer can go undetected until the cancer is at an advanced stage, making treatment more challenging.
GSK has stated that treatment options are urgently needed for patients with primary advanced or recurrent endometrial cancer. The company believes that the combination of its new drug dostarlimab and chemotherapy could offer a new treatment option for these patients. According to the results of a phase three trial released in March, the combination of dostarlimab and chemotherapy had a “statistically significant and clinically meaningful benefit” compared to a placebo and chemotherapy, according to GSK.
Hesham Abdullah, the head of GSK’s oncology development, said in a statement that this combination could change the treatment paradigm for this condition. “These patients currently face significant unmet medical needs, and this combination could change the treatment paradigm for this condition,” he said. GSK stated that the EMA committee will formally begin reviewing the drug and then give its opinion to the European Commission, which usually approves the watchdog’s recommendations.
If approved by the EMA, dostarlimab would offer a new treatment option for patients suffering from endometrial cancer. The drug is currently undergoing regulatory review in the United States, with GSK expecting the review to start in the first half of this year.
According to GSK, the number of endometrial cancer cases is expected to increase by almost 40% by 2040. This projection highlights the importance of developing new treatments that can effectively combat the disease. GSK’s dostarlimab and chemotherapy combination has the potential to become a significant part of the treatment regimen for endometrial cancer patients, especially those with advanced or recurring forms of the disease.
The approval of new treatments for cancer is a lengthy and complicated process that involves rigorous testing and evaluation. Despite the challenges, GSK remains committed to advancing its cancer research program and developing new treatments for patients. The company’s oncology portfolio includes a range of drugs that target different types of cancer, including solid tumors and blood cancers.
GSK’s oncology pipeline includes several promising drug candidates that are currently in development. These include a new drug for ovarian cancer, which is currently in phase two clinical trials, and a new drug for multiple myeloma, which is also in phase two clinical trials.
The development of new cancer treatments is essential to improve the quality of life and survival rates for cancer patients. GSK’s commitment to cancer research and its investment in developing new treatments are crucial in the fight against cancer. The company’s dostarlimab and chemotherapy combination could offer new hope for patients suffering from endometrial cancer, and the EMA’s review of the drug is an important step towards making this treatment option available to patients in Europe.
Furthermore, if the drug is approved by regulatory bodies in Europe and the United States, it could potentially offer a new treatment option for women with endometrial cancer worldwide, including in Nigeria. This could have a positive impact on the health outcomes of Nigerian women who are diagnosed with this type of cancer.